The FDA has granted orphan drug status to Vical's vaccine for the herpes virus cytomegalovirus. A mid-stage trial is planned for the second part of the year among bone marrow donors and recipients. The virus occurs in about 30 percent to 60 percent of bone marrow and solid organ transplant patients.
- read this article from the AP for more